Clinical trial
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
NCT00137800 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00137800 |
|---|---|
| Title | Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients |
| Official title | A Phase II Study of OSI-774 (Tarceva) in Elderly Subjects With Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Massachusetts General Hospital Brigham and Women's Hospital Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | OSI-774 (Tarceva) |
| Enrollment | 82 |
| Start date | Feb 1, 2003 |
| Primary completion | May 1, 2005 |
| Completion | Mar 1, 2007 |
| First posted | Aug 30, 2005 |
| Last update posted | Apr 3, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: